The company will use the capital to advance the development stage of its advanced breast cancer molecule drug. OrbiMed led the funding round, according to an Oct. 20 PIC Therapeutics news release.
“This financing from a committed and distinguished investor syndicate, which includes new and existing investors, underscores the progress we’ve made to advance our lead program toward our goal of cancer therapies that broadly address cancer-driving oncogenes via a fundamental mechanism in protein translational modulation,” PIC CEO Katherine Bowdish said. “We are well positioned to build a leading mechanistic-based oncology company that brings promising science to cancer patients with drug-resistant tumors.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
